Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04477603 · ClinicalTrials.gov registry record · NA
Impella ECP Early Feasibility Study
A NA study of High-risk Percutaneous Coronary Intervention, sponsored by Abiomed.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT04477603 is a NA study of High-risk Percutaneous Coronary Intervention that is active but no longer recruiting, run by Abiomed. The registered enrollment target is 100 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT04477603, a NA study of High-risk Percutaneous Coronary Intervention, is active but no longer recruiting, sponsored by Abiomed.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Impella ECP EFS is a prospective, multicenter, single-arm, feasibility study evaluating the safety of the Impella ECP device in adult patients undergoing an elective or urgent high-risk percutaneous coronary intervention.
Conditions Studied
Interventions
- DEVICE Impella ECP
Study Locations (5)
Michigan
- Henry Ford Hospital - Detroit
- Henry Ford Health St. John Hospital - Detroit
Massachusetts
- Tufts Medical Center - Boston
New Jersey
- The Valley Hospital - Paramus
Ohio
- The Christ Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2026-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04477603
The ClinicalTrials.gov registry entry for NCT04477603 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abiomed, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-risk Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 1 intervention - of which Impella ECP is the first listed.
NCT04477603 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04477603 about?
NCT04477603 is a clinical study titled "Impella ECP Early Feasibility Study". The Impella ECP EFS is a prospective, multicenter, single-arm, feasibility study evaluating the safety of the Impella ECP device in adult patients undergoing an elective or urgent high-risk percutaneous coronary intervention.
What is the current status of trial NCT04477603?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2020-10-09. Estimated completion is 2026-10-31.
What conditions does trial NCT04477603 study?
This clinical trial studies the following conditions: High-risk Percutaneous Coronary Intervention.
What interventions are being tested in trial NCT04477603?
The interventions under investigation include: Impella ECP (DEVICE).
Who is sponsoring clinical trial NCT04477603?
This trial is sponsored by Abiomed, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04477603 being conducted?
This trial has 5 study locations across Massachusetts, Michigan, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-risk Percutaneous Coronary Intervention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.